Global Protein Therapeutics Market 2016-2020

Published: November 2015
No. of Pages: 130
   

Market outlook of the protein therapeutics market

The market research analyst predicts the global protein therapeutics market to grow steadily at a CAGR of 8% during the forecast period. Increased demand for and use of monoclonal antibodies is expected to drive the growth of the protein therapeutics market as it accounts for more than half of the protein therapeutics market. The monoclonal antibodies can be prepared specific to any cell surface or extracellular target. These antibodies are being used in radioimmunotherapy and antibody-directed enzyme prodrug therapy. Monoclonal antibodies are also used in the formulation of various biopharmaceutical drugs for the treatment of different diseases such as cancer, rheumatoid arthritis, multiple sclerosis, and UC.

The availability of favorable reimbursement policies in this market is expected to boost the market growth during the forecast period. Protein therapeutics are expensive and cannot be afforded by all, but reimbursement of the diagnostic kits and biologic drugs are expected to fuel the market during the forecast period. Plans like the public reimbursement programs reduce the financial burden of treatments. The reimbursement status of drugs varies from region to region, with factors such as lack of cost-effectiveness impeding the coverage.

Product segmentation and analysis of the protein therapeutics market

  • Monoclonal antibodies
  • Erythropoietin
  • Insulin
  • Human growth hormone
  • Interferons
  • Blood clotting factor
  • G-CSF
  • Follicle stimulating hormone

The monoclonal antibodies segment dominated the market during 2015, with a market share of 55%. An increase in the prevalence of cancer and autoimmune diseases, increase in research activities, and increased technological advancement in the development of next-generation antibodies are the main factors fueling the growth of this segment.

Geographical segmentation and analysis of the protein therapeutics market

  • Americas
  • APAC
  • EMEA

The Americas accounted for 48% of the market share during 2015 and is expected to grow at a CAGR of 7% during the forecast period. The promising public health approaches by the government, growing incidence, and an increase in regulatory support for the development of protein therapeutics are the primary drivers for the market growth in this region.

Competitive landscape and key vendors

The global protein therapeutics market is highly fragmented due to the presence of numerous small and large vendors. The vendors in the market compete on the basis of price, quality, and innovation. Competition among the vendors has led an increased number of M&A, wherein smaller entities are being acquired by, or are being merged with, major players.

The leading vendors in the market are -

  • AbbVie
  • Amgen
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Merck
  • Novo Nordisk

Other prominent vendors in the market include Anhui Anke Biotechnology, AstraZeneca, Baxter International, Biocon, Biodel, Biogenomics, BioPartners, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Chugai Pharmaceutical, Diamyd Medical, Diasome Pharmaceuticals, DiaVacs, Dynavax Technologies, Eli Lilly, Ferring Pharmaceuticals, Generex Biotechnology, GeneScience Pharmaceuticals, Hualan Biological Engineering, Intas Pharmaceuticals, Ipsen, JCR Pharmaceuticals, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, LG Life Sciences, Macrogenics, MannKind, Oramed Pharmaceuticals, Osiris Therapeutics, Pfizer, Sandoz International, Sanofi, Teva Pharmaceutical Industries, Thermalin Diabetes, Tolerion, Wockhardt, and XOMA.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2020
  • What are the key factors driving the global protein therapeutics market
  • What are the key market trends impacting the growth of the protein therapeutics market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the vendors in the global protein therapeutics market
  • Trending factors influencing the market shares of the Americas, APAC, and EMEA
  • What are the key outcomes of the five forces analysis of the protein therapeutics market

Global Protein Therapeutics Market 2016-2020

Table of Contents

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 06: Market segmentation by product type

PART 07: Global monoclonal antibody drugs market
Introduction
Market overview
Market drivers
Market challenges
Market trends
Vendors of global monoclonal antibody drugs market

PART 08: Global insulin market
Introduction
Market overview
Market drivers
Market challenges
Market trends
Insulin market in Europe
Vendors of global insulin market

PART 09: Global erythropoietin market
Introduction
Market overview
Market drivers
Market challenges
Market trends
Erythropoietin market in Japan
Vendors of global erythropoietin market

PART 10: Global human growth hormone market
Introduction
Market overview
Market drivers
Market challenges
Market trends
Vendors of global human growth hormone market

PART 11: Market segmentation by therapy area
Metabolic and endocrine disorders
Hematopoiesis
Fertility
Cancer
Autoimmune diseases
Infectious diseases
Protein vaccine

PART 12: Market segmentation by protein function
Enzymatic and regulatory activity
Special targeting activity
Vaccines
Protein diagnostics

PART 13: Geographical segmentation
Global protein therapeutics market by geographical segmentation 2015-2020
Protein therapeutics market in Americas
Protein therapeutics market in EMEA
Protein therapeutics market in APAC

PART 14: Market drivers
Increased demand for monoclonal antibodies
Availability of favorable reimbursement policies
Increasing prevalence of chronic diseases
Promising drug pipeline
Frequent innovations

PART 15: Impact of drivers

PART 16: Market challenges
Patent expiration of top-selling drugs
Stringent regulations
High cost of therapy
Fierce market competition
Risk of side effects

PART 17: Impact of drivers and challenges

PART 18: Market trends
Patient assistance programs
Strategic alliances
Emergence of targeted therapies
Shifting focus toward untapped markets
Increase in public awareness

PART 19: Vendor landscape
Competitive scenario
Market share analysis 2015
Other prominent vendors

PART 20: Key vendor analysis
AbbVie
Amgen
F.Hoffmann-La Roche
Johnson & Johnson
Merck Serono
Novo Nordisk

PART 21: Appendix
List of abbreviations

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Global protein therapeutics market 2015-2020 ($ billions)
Exhibit 03: Five forces analysis
Exhibit 04: Segmentation of global protein therapeutics market by product type
Exhibit 05: Global protein therapeutic market segment by product type based on revenue, 2015
Exhibit 06: Top-selling monoclonal antibodies based on revenue, 2014 ($ billions)
Exhibit 07: Global monoclonal antibody market 2015-2020 ($ billions)
Exhibit 08: Global human insulin market 2015-2020 ($ billions)
Exhibit 09: Insulin market in Europe 2015-2020 ($ billions)
Exhibit 10: Globally approved erythropoietin biosimilars
Exhibit 11: Global erythropoietin market 2015-2020 ($ billions)
Exhibit 12: Erythropoietin market in Japan 2015-2020 ($ millions)
Exhibit 13: Global human growth hormone market 2015-2020 ($ billions)
Exhibit 14: Segmentation of global protein therapeutics market by therapy area
Exhibit 15: Segmentation of global protein therapeutics market by protein function
Exhibit 16: Global protein therapeutics market by geography, 2015
Exhibit 17: Global protein therapeutics market revenue by geography 2015-2020 ($ billions)
Exhibit 18: Protein therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 19: Protein therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 20: Protein therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 21: Monoclonal antibody approvals by FDA and EMA from 2010-2014
Exhibit 22: Impact of drivers
Exhibit 23: Impact of drivers and challenges
Exhibit 24: Roche: YoY growth and revenue generated from net product sales of Actemra 2011-2014 ($ millions)
Exhibit 25: Roche: YoY growth and revenue generated from net product sales of Avastin 2011-2014 ($ millions)
Exhibit 26: Roche: YoY growth and revenue generated from net product sales of Herceptin 2011-2014 ($ millions)
Exhibit 27: Roche: Revenue generated from net product sales of Kadcyla 2013-2014 ($ millions)
Exhibit 28: Roche: YoY growth and revenue generated from net product sales of Lucentis 2011-2014 ($ millions)
Exhibit 29: Roche: YoY growth and revenue generated from net product sales of MabThera/Rituxan 2011-2014 ($ millions)
Exhibit 30: Roche: YoY growth and revenue generated from net product sales of Mircera 2011-2014 ($ millions)
Exhibit 31: Roche: YoY growth and revenue generated from net product sales of NeoRecorm/Epogin 2011-2014 ($ millions)
Exhibit 32: Roche: YoY growth and revenue generated from net product sales of Pegasys 2011-2014 ($ millions)
Exhibit 33: Roche: YoY growth and revenue generated from net product sales of Perjeta 2012-2014 ($ millions)
Exhibit 34: Roche: YoY growth and revenue generated from net product sales of Pulmozyme 2011-2014 ($ millions)
Exhibit 35: Novo Nordisk: Revenue generated from net product sales of new-generation insulins 2013-2014 ($ millions)
Exhibit 36: Novo Nordisk: YoY growth and revenue generated from net product sales of Levemir 2011-2014 ($ millions)
Exhibit 37: Novo Nordisk: YoY growth and revenue generated from net product sales of NovoRapid/NovoLog 2011-2014 ($ millions)
Exhibit 38: Novo Nordisk: YoY growth and revenue generated from net product sales of NovoMix 2011-2014 ($ millions)
Exhibit 39: Novo Nordisk: YoY growth and revenue generated from net product sales of human insulins 2011-2014 ($ millions)
Exhibit 40: Novo Nordisk: YoY growth and revenue generated from net product sales of NovoSeven 2011-2014 ($ millions)
Exhibit 41: Novo Nordisk: YoY growth and revenue generated from net product sales of Norditropin 2011-2014 ($ millions)
Exhibit 42: Amgen: YoY growth and revenue generated from net product sales of Aranesp 2011-2014 ($ millions)
Exhibit 43: Amgen: YoY growth and revenue generated from net product sales of Enbrel 2011-2014 ($ millions)
Exhibit 44: Amgen: YoY growth and revenue generated from net product sales of EPOGEN 2011-2014 ($ millions)
Exhibit 45: Amgen: YoY growth and revenue generated from net product sales of Neulasta 2011-2014 ($ millions)
Exhibit 46: Amgen: YoY growth and revenue generated from net product sales of NEUPOGEN 2011-2014 ($ millions)
Exhibit 47: Amgen: YoY growth and revenue generated from net product sales of Vectibix 2011-2014 (excluding Japan) ($ millions)
Exhibit 48: Amgen: YoY growth and revenue generated from net product sales of XGEVA 2011-2014 ($ millions)
Exhibit 49: Amgen: YoY growth and revenue generated from net product sales of Prolia 2011-2014 ($ millions)
Exhibit 50: AbbVie: YoY growth and revenue generated from net product sales of HUMIRA 2011-2014 ($ millions)
Exhibit 51: AbbVie: YoY growth and revenue generated from net product sales of Synagis 2011-2014 ($ millions)
Exhibit 52: AbbVie: YoY growth and revenue generated from net product sales of Lupron 2011-2014 ($ millions)
Exhibit 53: Johnson & Johnson: YoY growth and revenue generated from net product sales of Procrit 2011-2014 ($ millions)
Exhibit 54: Johnson & Johnson: YoY growth and revenue generated from net product sales of Remicade 2011-2014 ($ millions)
Exhibit 55: Johnson & Johnson: YoY growth and revenue generated from net product sales of Simponi 2011-2014 ($ millions)
Exhibit 56: Johnson & Johnson: YoY growth and revenue generated from net product sales of Stelara 2011-2014 ($ millions)
Exhibit 57: Merck: YoY growth and revenue generated from net product sales of Erbitux except US and Canada 2011-2014 ($ millions)
Exhibit 58: Merck: YoY growth and revenue generated from net product sales of Pegintron 2011-2014 ($ millions)
Exhibit 59: Merck: YoY growth and revenue generated from net product sales of Remicade 2011-2014 ($ millions)
Exhibit 60: Merck: YoY growth and revenue generated from net product sales of Simponi 2011-2014 ($ millions)
Exhibit 61: AbbVie: Product segmentation by revenue 2014
Exhibit 62: AbbVie: Product segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 63: AbbVie: Geographical segmentation by revenue 2014
Exhibit 64: Amgen: Business segmentation by revenue 2014
Exhibit 65: Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 66: Amgen: Geographical segmentation by revenue 2014
Exhibit 67: Roche: Business segmentation by revenue 2014
Exhibit 68: Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 69: Roche: Geographical segmentation by revenue 2014
Exhibit 70: Johnson & Johnson: Business segmentation
Exhibit 71: Merck Serono: Product segmentation 2014
Exhibit 72: Merck Serono: Geographical segmentation by revenue 2014
Exhibit 73: Novo Nordisk: Business segmentation by revenue 2014
Exhibit 74: Novo Nordisk: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 75: Novo Nordisk: Geographical segmentation by revenue 2014
Exhibit 76: Novo Nordisk: R&D expenditure 2014

Published By: Infiniti Research Limited
Product Code: Infiniti Research Limited9723


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we´┐Żll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: